Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2022-12-12
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EG04
|
| gptkbp:brand |
gptkb:Krazati
|
| gptkbp:CASNumber |
gptkb:2389149-74-6
|
| gptkbp:chemicalFormula |
C32H35ClFN7O2
|
| gptkbp:developedBy |
gptkb:Mirati_Therapeutics
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:adagrasib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Krazati
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
KRAS G12C inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue liver enzyme elevation |
| gptkbp:target |
KRAS G12C mutation
|
| gptkbp:bfsParent |
gptkb:adagrasib
|
| gptkbp:bfsLayer |
6
|